Agile Therapeutics

Agile Therapeutics, Inc. is a healthcare company, which engages in the development and commercialization of transdermal patch. Its lead product candidate, Twirla, also known as AG200-15, is an investigational low-dose, non-daily prescription contraceptive. The company was founded by Chien Te Yen on December 22, 1997 and is headquartered in Princeton, NJ.

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Agile Therapeutics is a specialty pharmaceutical company that engages in the development of women's healthcare products. It offers a low estrogen dose seven-day transdermal contraceptive patch system that delivers a combination of levonorgestrel and ethinylestradiol. This is a forward-thinking women's healthcare company dedicated to fulfilling the unmet health needs of today’s women.

Agile Therapeutics, Inc. (AGRX) CEO Alfred Altomari on Q2 2020 Results - Earnings Call Transcript

PRINCETON, N.J., Aug.  11, 2020  (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX), a women's healthcare company, today announced that Al Altomari, Chairman and Chief Executive Officer, will participate in a panel discussion as part of Maxim Group’s M-Vest Virtual Conference Series: Leading Innovators in Women’s Health, beginning at 10:00 a.m. Eastern Time on Thursday, August 13, 2020. The panel will be moderated by Jason McCarthy, PhD, lead biotechnology analyst at Maxim Group.

Agile Therapeutics to Participate in Maxim Group’s Leading Innovators in Women’s Health Virtual Conference

Live Conference Call and Webcast at 4:30 p.m. ET

Agile Therapeutics to Host Second Quarter 2020 Financial Results and Business Update Conference Call on Tuesday, August 11, 2020

Agile Therapeutics (AGRX) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

How Agile Therapeutics (AGRX) Stock Stands Out in a Strong Industry

PRINCETON, N.J., June  16, 2020  (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX), a women’s healthcare company, today announced that the Company will be added to the Russell 3000® and 2000® Indexes, effective after the U.S. market opens on June 29, 2020, as part of the Russell Indexes annual reconstitution.

Agile Therapeutics to Join Russell 3000® and 2000® Indexes

Agile Therapeutics, Inc. (AGRX) CEO Alfred Altomari on Q1 2020 Results - Earnings Call Transcript

Investors need to pay close attention to Agile Therapeutics (AGRX) stock based on the movements in the options market lately.

Is the Options Market Predicting a Spike in Agile Therapeutics (AGRX) Stock?

Agile's shares are heating up ahead of the company's Q1 earnings report.

Why Agile Therapeutics Stock Is Jumping Today

Agile Therapeutics: Billion Dollar Buy-Out Is On The Horizon

PRINCETON, N.J., April  22, 2020  (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX), a forward-thinking women’s healthcare company, today announced that the company has nominated Sharon Barbari for election as a class III director to replace Abhijeet Lele, a member of the company’s board of directors and the board’s Lead Independent Director, who will not stand for re-election and cease to be a director on June 9, 2020, the date of the company’s Annual Meeting of Stockholders. In addition, William McKee has informed the company that he will retire from the company’s board of directors effective June 9, 2020. The company plans to appoint Sandra Carson, M.D., FACOG as a class II director to replace Mr. McKee when he retires.

Agile Therapeutics Announces Changes to its Board of Directors

Agile Therapeutics (AGRX) closed at $1.86 in the latest trading session, marking no change from the prior day.

Agile Therapeutics (AGRX) Flat As Market Sinks: What You Should Know

Implied Volatility Surging for Agile Therapeutics (AGRX) Stock Options

The biotech stock is getting hit hard by the marketwide downturn today. Here's why.

Why Agile Therapeutics Stock Is Crashing Today

Agile's stock can't seem to find a bottom, despite a major regulatory approval earlier this month.

Why Agile Therapeutics Stock Is Getting Crushed Today

Shares drop after the company releases the pricing details of a recently announced capital raise.

Why Agile Therapeutics Stock Is Falling Today

Agile Therapeutics (AGRX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Agile Therapeutics (AGRX) Upgraded to Buy: Here's Why

Is  (AGRX) Outperforming Other Medical Stocks This Year?

Is Agile Therapeutics (AGRX) Stock Outpacing Its Medical Peers This Year?

PRINCETON, N.J., Feb.  21, 2020  (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX), a women’s healthcare company, today announced the pricing of its underwritten public offering of 15 million shares of its common stock at a public offering price of $3.00 per share. The gross proceeds from the offering, before deducting underwriting discounts and commissions and estimated offering expenses payable by Agile Therapeutics, are expected to be approximately $45 million. In addition, Agile Therapeutics has granted the underwriters a 30-day option to purchase up to 2.25 million additional shares of common stock at the public offering price, less the underwriting discounts and commissions. All shares in the offering will be sold by Agile Therapeutics.

Agile Therapeutics Announces Pricing of $45 Million Underwritten Public Offering of Common Stock

PRINCETON, N.J., Feb.  20, 2020  (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX), a women’s healthcare company, today announced that it intends to offer and sell shares of its common stock in an underwritten public offering. All shares being offered are to be sold by Agile Therapeutics.  Agile Therapeutics intends to grant the underwriters a 30-day option to purchase an additional fifteen percent of the shares of common stock offered in the public offering.  The proposed offering is subject to market and other conditions, and there can be no assurances as to whether or when the offering may be completed, or as to the actual size or terms of the offering. 

Agile Therapeutics Announces Proposed Underwritten Public Offering of Common Stock

Twirla now has a green light from the FDA. And that could mean a green light for investors looking for a promising small-cap biotech stock.

Is Agile Therapeutics Stock a Buy After Its Big FDA Win?

Agile Therapeutics Inc. (NASDAQ: AGRX) shares took a dip on Tuesday after the company announced a key U.S.

Why This Analyst Sees New Contraceptive FDA Approval Doubling Agile Therapeutics Stock

Medicines

Agile Could Reach $10/Share After Twirla Approval

Coronavirus is having a major impact across sectors.

Agile's Approval, And Other News: The Good, Bad And Ugly Of Biopharma

Twirla® is a new non-daily, non-invasive contraceptive approved in the U.S.

FDA Approves Agile Therapeutics, Inc.’s Twirla® (levonorgestrel and ethinyl estradiol) Transdermal System

The drugmaker is borrowing money to tide it over until it can hopefully achieve commercial success for its first product.

News for Agile Therapeutics Stock (AGRX)